CGRP Migraine Drugs Are Generally Safe for People With Raynaud Phenomenon
Microvascular complications from CGRP antagonist use in migraine patients with Raynaud phenomenon are uncommon (5.3%), though rare serious events including digital necrosis warrant caution.
Quick Facts
What This Study Found
5.3% of migraine patients with Raynaud phenomenon experienced microvascular complications from CGRP antagonists, including rare but serious events like gangrene requiring digit amputation.
Key Numbers
169 patients; 9 (5.3%) complications; erenumab in 5, galcanezumab in 3, fremanezumab in 1; amputation in severe cases
How They Did This
Retrospective cohort study at Mayo Clinic (May 2018 - September 2020) of 169 patients with both migraine and Raynaud phenomenon who received CGRP antagonist therapy.
Why This Research Matters
CGRP antagonists are highly effective migraine treatments, but their vasodilatory blockade poses theoretical risks for patients with vascular conditions. This study provides the first systematic safety data for this specific at-risk population.
The Bigger Picture
As CGRP-targeting drugs become first-line migraine treatments, understanding their safety in patients with comorbid vascular conditions is critical. This study fills an important knowledge gap and provides practical guidance for prescribing decisions.
What This Study Doesn't Tell Us
Retrospective single-center design. Small number of complication cases (n=9) limits statistical power for identifying risk factors. Potential ascertainment bias at a referral center.
Questions This Raises
- ?Are there specific risk factors that predict which Raynaud patients will develop complications on CGRP antagonists?
- ?Should Raynaud patients be screened or monitored differently when starting CGRP therapy?
- ?Do gepants (oral CGRP antagonists) carry the same risk as monoclonal antibodies in this population?
Trust & Context
- Key Stat:
- 5.3% complication rate In migraine patients with Raynaud phenomenon, ranging from worsened symptoms to gangrene
- Evidence Grade:
- Retrospective cohort study from a major academic center. Moderate evidence quality limited by small complication numbers and lack of comparison group.
- Study Age:
- Published in 2021, covering data from the early clinical experience with CGRP antagonists (2018-2020).
- Original Title:
- Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon.
- Published In:
- JAMA network open, 4(4), e217934 (2021)
- Authors:
- Breen, Ilana D, Brumfiel, Caitlin M, Patel, Meera H, Butterfield, Richard J, VanderPluym, Juliana H, Griffing, Leroy, Pittelkow, Mark R, Mangold, Aaron R
- Database ID:
- RPEP-05292
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Is it safe to take CGRP migraine drugs if you have Raynaud's?
For most patients, yes — 94.7% in this study experienced no microvascular complications. However, 5.3% did develop problems ranging from worsened Raynaud symptoms to rare serious events. Your doctor should monitor you more closely if you have both conditions.
Why could CGRP drugs affect Raynaud phenomenon?
CGRP is a peptide that helps blood vessels dilate. Blocking it with migraine drugs can reduce this protective dilation. In people with Raynaud phenomenon, whose blood vessels already spasm excessively in fingers and toes, this loss of dilation can sometimes worsen symptoms or, rarely, cause tissue damage.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05292APA
Breen, Ilana D; Brumfiel, Caitlin M; Patel, Meera H; Butterfield, Richard J; VanderPluym, Juliana H; Griffing, Leroy; Pittelkow, Mark R; Mangold, Aaron R. (2021). Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon.. JAMA network open, 4(4), e217934. https://doi.org/10.1001/jamanetworkopen.2021.7934
MLA
Breen, Ilana D, et al. "Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon.." JAMA network open, 2021. https://doi.org/10.1001/jamanetworkopen.2021.7934
RethinkPeptides
RethinkPeptides Research Database. "Evaluation of the Safety of Calcitonin Gene-Related Peptide ..." RPEP-05292. Retrieved from https://rethinkpeptides.com/research/breen-2021-evaluation-of-the-safety
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.